scholarly journals PTEN functions as a melanoma tumor suppressor by promoting host immune response

Oncogene ◽  
2013 ◽  
Vol 33 (38) ◽  
pp. 4632-4642 ◽  
Author(s):  
Y Dong ◽  
J-AE Richards ◽  
R Gupta ◽  
P P Aung ◽  
A Emley ◽  
...  
Keyword(s):  
Immune Response ◽  
Tumor Suppressor ◽  
Host Immune Response ◽  
Melanoma Tumor

scholarly journals Tumor suppressor maspin as a modulator of host immune response to cancer

2015 ◽  
Vol 15 (4) ◽  
Author(s):  
Sijana H. Dzinic ◽  
Maria M. Bernardo ◽  
Daniel S.M. Oliveira ◽  
Marian Wahba ◽  
Wael Sakr ◽  
...  
Keyword(s):  
Immune Response ◽  
Tumor Suppressor ◽  
Host Immune Response ◽  
Immune Response To Cancer

scholarly journals Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature

2020 ◽  
Vol 18 (5) ◽  
pp. 517-521 ◽  
Author(s):  
Saranya Chumsri ◽  
Ethan S. Sokol ◽  
Aixa E. Soyano-Muller ◽  
Ricardo D. Parrondo ◽  
Gina A. Reynolds ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immune Response ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Complete Response ◽  
Host Immune Response ◽  
Melanoma Tumor ◽  
Mutational Burden ◽  
Tumor Mutational Burden ◽  
Durable Complete Response

Increasing data support the importance of preexisting host immune response and neoantigen burden for determining response to immune checkpoint inhibitors (ICIs). In lung cancer and melanoma, tumor mutational burden (TMB) has emerged as an independent biomarker for ICI response. However, the significance of TMB in breast cancer, particularly in the context of PD-L1 negativity, remains unclear. This report describes a patient with HER2-negative breast cancer with high TMB and an apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) trinucleotide signature; her disease was refractory to multiple lines of treatments but achieved durable complete response using ICIs and capecitabine. Additional analysis of the tumor revealed a low amount of stromal tumor-infiltrating lymphocytes (sTILs) and PD-L1 negativity, reflecting a poor preexisting host immune response. In collaboration with Foundation Medicine, comprehensive genomic profiling from 14,867 patients with breast cancer with the FoundationOne test was evaluated. Using the cutoff of ≥10 mutations/megabase (mut/Mb) for high TMB, PD-L1 positivity and TMB-high populations were not significantly overlapping (odds ratio, 1.02; P=.87). Up to 79% of TMB-high tumors with >20 mut/Mb were PD-L1–negative. Our study highlights that despite having low TILs and PD-L1 negativity, some patients may still experience response to ICIs.

scholarly journals Human Norovirus Proteins: Implications in the Replicative Cycle, Pathogenesis, and the Host Immune Response

2020 ◽  
Vol 11 ◽  
Author(s):  
Claudia P. Campillay-Véliz ◽  
Jonatan J. Carvajal ◽  
Andrea M. Avellaneda ◽  
Darling Escobar ◽  
Camila Covián ◽  
...  
Keyword(s):  
Immune Response ◽  
Host Immune Response ◽  
Human Norovirus ◽  
Replicative Cycle
Sign in / Sign up

Export Citation Format

Share Document